Three main injectable drug classes are often used in the treatment of keloids and hypertrophic scars: corticosteroids (CS), antimetabolites (e.g. 5-fluorouracil [5-FU]), and anti-tumour agents (e.g. bleomycin) [1,2]. Among other things, steroids suppress the inflammatory process, reduce the synthesis of collagen and glycosaminoglycans, and inhibit fibroblast growth [3].
The most commonly used CS is triamcinolone acetonide (TAC) in a dose of 10-40 mg/mL; but different treatment intervals are reported on in literature [3]. Used as monotherapy, CS are primarily efficacious in 50%-100% but show a substantial recurrence rate of 9%-50% [3]. In a comparison between TAC injections and 5-FU injections over 6 months, no statistical significance was found, but 5-FU had fewer local adverse events such as skin atrophy (TAC 44% vs 5-FU 8%) or telangiectasia (TAC 50% vs 5-FU 21%) [4]. Superior results were achieved by a combination of TAC/5-FU, which showed no recurrence at 6-months follow-up [5]. The combination may also have fewer adverse effects [3]. When tested against 5-FU, bleomycin had better data for efficacy and remission that were irrespective of age, sex, scar site, and duration of disease [6]. Recurrence rates for monotherapy with bleomycin were 0-15% [3]. Besides TAC and 5-FU, botulinum toxin A is currently being investigated and has been shown to modulate activity of keloids and hypertrophic scars by acting on expression of fibroblast and modulating their activity [7-10].
The injections themselves can be painful, but so can the administration of lidocaine [11]. “Benzyl alcohol in bacteriostatic saline is a preservative. It gives you 30 seconds of painless anaesthesia,” was the practice tip of Dr David M. Ozog (Henry Ford Hospital, USA). He advised a preload of bacteriostatic saline to be immediately followed by lidocaine into the centre of the saline. “You have to do it quickly,” Dr Ozog added. “You cannot inject the bolus of benzyl alcohol and then wait a little with the lidocaine - it has to be right there.”
- Dierickx C. 24th World Congress of Dermatology, 10-15 June 2019, Milan, Italy.
- Ogawa R. Int J Mol Sci. 2017;18: E606.
- Jones CD, et al. Dermatol Reports. 2015;7: 5880.
- Hietanen KE, et al. J Plast Reconstr Aesthet Surg. 2019;72: 4-11.
- Khan MA, et al. J Pak Med Assoc. 2014 Sep;64: 1003-7.
- Kabel AM, et al. J Dermatol & Dermatol Surg. 2016;20(1):32–38.
- Tretti Clementoni M. 24th World Congress of Dermatology, 10-15 June 2019, Milan, Italy.
- Austin E, et al. Dermatol Surg. 2018;44: 149-157.
- Gupta S. 24th World Congress of Dermatology, 10-15 June 2019, Milan, Italy.
- Kasyanju Carrero LM, et al. J Cosmet Dermatol. 2019;18: 10-15.
- Ozog DM. 24th World Congress of Dermatology, 10-15 June 2019, Milan, Italy.
Posted on
Previous Article
« Long awaited oral therapy for moderate-to-severe AD Next Article
Management strategies for drug-induced mucositis »
« Long awaited oral therapy for moderate-to-severe AD Next Article
Management strategies for drug-induced mucositis »
Table of Contents: WCD 2019
Featured articles
Letter from the Editor
Insights into pathogenesis of AD define novel therapeutic targets
Treating Psoriasis in 2019
Choosing the right biologic in psoriasis
Registries – an important research tool in biologics
Atopic Dermatitis – What is New
Insights into pathogenesis of AD define novel therapeutic targets
Combinations are hot in AD treatment
Dermal Reactions to Systemic Drugs
Cutaneous adverse events due to EGFR inhibitors
Management strategies for drug-induced mucositis
Skin toxicity of immune checkpoint inhibitors
Lupus Erythematosus Today
New targets and biologics for cutaneous lupus erythematosus
Novel lupus classification will aid future research
Hidradenitis Suppurativa
Various guidelines with much overlap
Antibiotics in hidradenitis suppurativa
Biologicals beyond TNF blockade
Small Molecules – What to Expect
Novel treatment options for many dermatologic indications
Long awaited oral therapy for moderate-to-severe AD
Novel treatment options in alopecia areata and vitiligo
Optimising the Management of Keloids
Keloids: a faulty switch in wound healing?
What the future of keloid treatment could hold
Malignant Melanoma – Advances in Management
Will malignant melanoma become a curable disease?
Best of the Posters
Related Articles
December 9, 2019
Biologics: increasingly used in paediatric dermatology
August 6, 2020
Psoriasis therapy for children and pregnancies
November 5, 2022
Novel oral psoriasis drug maintains efficacy over 2 years
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy